Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Transfusion01:15

Blood Transfusion

Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thalassaemia.

Nature reviews. Disease primers·2026
Same author

Addressing Obstetric and Gynecologic Needs in Thalassemia.

O&G open·2026
Same author

Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease.

Hemoglobin·2026
Same author

Scientific progress in the shadow of regional instability.

The Lancet. Haematology·2026
Same author

Implications of changes in WHO haemoglobin elevation adjustment guidelines on global, regional, and national anaemia burden, 1990-2023: a population-based modelling study.

The Lancet. Haematology·2026
Same author

Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial.

European journal of haematology·2026

Related Experiment Video

Updated: May 10, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Non-transfusion-dependent thalassemias.

Khaled M Musallam1, Stefano Rivella, Elliott Vichinsky

  • 1Department of Medicine and Medical Specialties, IRCCS Ca’ Granda Foundation Maggiore Policlinico Hospital, University of Milan, Milan, Italy. musallamk@gmail.com

Haematologica
|June 5, 2013
PubMed
Summary

Non-transfusion-dependent thalassemias, including beta-thalassemia intermedia and hemoglobin H disease, present unique challenges. Early diagnosis and novel therapeutics are crucial for managing complications like iron overload and hypercoagulability.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Related Experiment Videos

Last Updated: May 10, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Area of Science:

  • Hematology
  • Genetics
  • Internal Medicine

Background:

  • Non-transfusion-dependent thalassemias (NTDT) encompass diverse phenotypes, distinct from beta-thalassemia major, not requiring regular transfusions for survival.
  • Common forms include beta-thalassemia intermedia, hemoglobin E/beta-thalassemia, and alpha-thalassemia intermedia (hemoglobin H disease).
  • Despite transfusion independence, NTDT patients face significant morbidities due to ineffective erythropoiesis and peripheral hemolysis.

Purpose of the Study:

  • To highlight the importance of prompt and accurate diagnosis of NTDT for timely intervention.
  • To emphasize the need for novel therapeutic strategies based on advancing disease mechanism understanding.
  • To underscore the necessity of international collaboration in addressing the global spread of NTDT.

Main Methods:

  • This study is a review of current understanding and management of NTDT.
  • It synthesizes information on pathophysiology, clinical manifestations, and therapeutic approaches.
  • It discusses the evolving epidemiological landscape of NTDT.

Main Results:

  • NTDT are associated with serious pathophysiologies including iron overload and hypercoagulability.
  • Current management options exist, but novel therapeutics are warranted.
  • NTDT prevalence is increasing in non-endemic regions due to migration.

Conclusions:

  • Accurate diagnosis of NTDT is essential for early intervention and improved patient outcomes.
  • Further research and development of novel therapeutics are critical for managing NTDT complications.
  • International collaboration is vital to address the global health challenge posed by NTDT.